Selective CDK2 inhibitor developer advancing INX-315 for CDK4/6-resistant ER+/HER2- breast cancer and CCNE1-amplified solid tumors.
At a glance
- HQ: RTP
- Sector: Biotech
- Stage: Series B
- Total raised: $47M
- Last round: Series B
The rest of this record is behind a free account.
Founders, funding history, investor connections, and recent signals load on this page as soon as you sign in. Accounts open immediately, and I read every signup.